Kimberly-Clark Offers EU Concessions to Clear $40B Kenvue Deal
KVUE sits 28% above its 52-week low of $14.02.
Summary
Kimberly-Clark and Kenvue have submitted antitrust remedies to the European Commission, with an Oct. 13 deadline for the initial probe. This is a concrete step toward clearing the $40B acquisition in the EU, following Australia's conditional approval earlier this month. The concessions signal progress in the regulatory process, though the specific remedies remain undisclosed. The deal, agreed in November, still faces the revived Tylenol litigation and other regulatory hurdles. Watch for the EU's decision after Oct. 13.
At the time of this announcement, KVUE was trading at $17.90 on NYSE in the Trade & Services sector, with a market capitalization of approximately $34.3B. The 52-week trading range was $14.02 to $20.13. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Dow Jones Newswires.